FIGURE 1:

Patient disposition. A total of 1794 patients were enrolled in the Global aHUS Registry, of whom 151 patients were subsequently included in this analysis. These patients had been treated with eculizumab with clinical evidence of a response to therapy, and had received at least 1 month of therapy, AND had at least 6 months of follow-up after discontinuation OR had suffered a TMA recurrence within 6 months of follow-up. Additionally, patients fulfilling these criteria must also not have met any of the exclusion criteria.